Designing peptides to uncover cancer vulnerabilities at telomeres

Designing peptides to uncover cancer vulnerabilities at telomeres

Research Question and Applicant Fit

How can chromosome ends remain protected while being prepared for DNA replication? This chemical-biology PhD uses peptides as research tools to examine TRF2-centred shelterin interactions and ask whether ALT cancer cells are especially dependent on the proposed ORC–TRF2 preparation mechanism. The project should not be read as a proven cancer therapy: the peptide molecules are research probes and potential starting points, and the advertised cancer selectivity remains to be tested across ALT, telomerase-positive and normal cells.

The LMS 2026–27 recruitment page lists the project under the tPhD Programme with Christian Speck, Anna Barnard and Alexis Barr, and the application form lists it in the same round (LMS recruitment page, application form PDF, project document). The form gives a deadline of 18 November 2026, 9am UK time; the available records do not confirm whether applications are still being accepted. LMS describes a competitive four-year award with a £26,500 annual tax-free stipend, full tuition-fee coverage, research consumables and overseas visa costs, open to all nationalities (LMS recruitment page). Eligibility to apply does not guarantee an individual award.

Research Problem and Doctoral Work

What Is Unsolved and Why It Matters

Telomeres have a built-in contradiction: shelterin must restrict access to chromosome ends so they are not treated as broken DNA, but those protected ends still need to be prepared for replication. The advertised project focuses on an unexpected ORC-TRF2 connection: if ORC can bind TRF2 and reorganise shelterin, then telomere replication may depend on a specific protein-interaction switch rather than on generic replication machinery alone. The peptide-design angle matters because peptides can probe protein-protein interfaces that are difficult to test with small molecules, but they should be treated first as mechanistic tools.

The cancer rationale is specific to telomere maintenance. ALT cancer cells maintain telomeres through recombination and must balance repair-like activity with protection from destructive recombination, telomere loss or chromosome fusion. The project asks whether disrupting TRF2 interactions changes that balance and preferentially compromises ALT cancer cells compared with telomerase-positive cancer cells and normal cells. That is a testable vulnerability hypothesis, not an established therapy.

Work, Methods, and Potential Outputs

The likely PhD work has three connected layers. First, purified human proteins and quantitative binding measurements should map which TRF2 interactions matter for telomere replication and shelterin organisation. Second, peptide design, synthesis and optimisation should create probes that perturb those interactions. Third, human-cell experiments should test whether the perturbations alter telomere behaviour and cancer-cell survival. The public project description says existing interaction mutants allow cellular experiments to begin alongside peptide development, which is a useful feasibility signal, but it does not prove that peptide delivery or ALT selectivity is already solved.

Supervisor and Lab Assessment

Supervisor Research Directions

Christian Speck brings DNA replication licensing and ORC/MCM biochemistry; Anna Barnard brings chemical biology, peptides and perturbation of protein-protein interactions; Alexis Barr brings cell-cycle, cancer-cell imaging and perturbation-screen expertise (Speck profile, DNA Replication group, Anna Barnard profile, Barr profile, Cell Cycle Control group). The combination fits the advertised workflow unusually well: biochemistry defines the interface, chemistry builds the perturbing molecules, and cell biology tests whether telomere and survival phenotypes follow.

Recent Important Publications

Geminin inhibits DNA replication licensing by sterically blocking CDT1-MCM2 interactions (2025)

This study uses reconstituted DNA licensing and peptide/domain analysis to explain geminin's inhibition of the CDT1–MCM2 interaction. It supports the teams' ability to combine peptide chemistry, biochemical mechanism and DNA-replication research in a joint project. Geminin–CDT1–MCM2 is nevertheless a different system from TRF2–ORC–shelterin: the paper supports collaboration and methodological fit, not the proposed telomere vulnerability. Paper.

MCM2-7 loading-dependent ORC release ensures genome-wide origin licensing (2024)

The study explains ORC release within human genome-wide replication licensing. It supports the Speck laboratory's expertise in ORC/MCM mechanisms relevant to the advertised question, while genome-wide origin licensing remains distinct from telomere-specific shelterin organisation. Paper.

Reconstitution of human DNA licensing and the structural and functional analysis of key intermediates (2025)

Reconstitution with purified proteins and analysis of licensing intermediates provide relevant experience for quantitative protein-interaction work. This supports the proposed biochemical platform, but the study does not itself test ALT cancer-cell selectivity. Paper.

TRF2-mediated ORC recruitment underlies telomere stability upon DNA replication stress (2021)

This external field study links the TRF2–ORC interaction to telomere stability under replication stress. It gives a direct rationale for the project's telomere question; it is not evidence that its proposed peptide probes will work. It remains background evidence, separate from the recent team-related studies. Paper.

Lab, Resources, and Collaboration Environment

The project should benefit from LMS shared facilities and the physical proximity of LMS and Imperial groups in west London. Relevant support includes genomics, proteomics, light microscopy and bioinformatics, all of which match the likely readouts for telomere behaviour, protein interactions and quantitative cell phenotypes (LMS facilities overview, genomics facility, proteomics facility, light microscopy facility, bioinformatics facility). The main practical question is how the student's time is split across Speck, Barnard and Barr labs.

School, Programme, and Field Context

LMS is an MRC institute listed by UKRI, and LMS PhD students are enrolled through Imperial College London's Faculty of Medicine (UKRI MRC list, LMS PhD study page). Imperial adds strong institutional visibility, while LMS provides the specific biomedical institute environment (QS Imperial profile, Research at the LMS).

The advertised coordinated supervision spans protein biochemistry, peptide chemistry, computational modelling and quantitative cell imaging across the three nearby laboratories. These are training areas, not a requirement to arrive proficient in all of them. The saved material does not specify the full timetable of compulsory modules, progression assessments or laboratory rotations; confirm how cross-laboratory training and supervision will be coordinated.

Funding, Application, and Living Cost

LMS states successful applicants receive a four-year studentship with £26,500 per year tax-free stipend, full coverage of student tuition fees, all necessary research consumables and visa costs for overseas students. The programme is open to applicants of all nationalities, but award selection is competitive and not a personal guarantee. For Chinese applicants, the official all-nationalities wording supports eligibility to apply and the funding text supports full tuition-fee coverage if awarded. The offer/CAS stage should confirm the personal award terms and how overseas visa costs are paid or reimbursed. The saved coverage statement is clear about tuition; IHS, dependants and payment timing still need written clarification.

London cost is the main practical pressure. Imperial's 2026 living-cost estimates are the appropriate living-cost source for this programme, while UKVI guidance should be used for visa financial-evidence rules and CAS planning (Imperial living-cost estimates, UKVI financial evidence). The £26,500 stipend is strong for a UK PhD, but rent deposits and first-month costs still need planning.

Applicant Fit and Preparation

Academic Requirements and Research Fit

LMS states that applicants should have obtained, or expect to obtain, a first-class or upper-second-class degree or equivalent in a relevant scientific subject from a recognised university. A relevant master’s is preferred; equivalent research experience totalling at least one year may also be considered. These formal conditions are distinct from the examples of useful cross-disciplinary experience below.

Best-fit backgrounds include biochemistry, chemistry, molecular biology, chemical biology, peptide/protein chemistry and cancer cell biology. Applicants are not required to have experience in every area. A useful way to demonstrate fit is to connect relevant areas, for example, peptide/PPI design plus cell assays, or replication/telomere biology plus quantitative imaging. Imperial English-language requirements should be checked by applicants whose first language is not English (Imperial English requirements).

Preferred Experience and Suggested Preparation

Useful preparation is project-specific: read the Speck, Barnard and Barr sources; understand why TRF2 is both a shelterin component and a protein-interaction hub; prepare a concise explanation of how an in vitro binding effect could be validated in ALT and normal cells; and identify which skills are already evidenced versus which must be learned. This is preparation for the LMS case-for-support answers, not a separate formal research-proposal requirement unless LMS asks for one.

Career and Transferable Skills

The field context is favourable for chemical-biology, cancer-mechanism and data-rich cell-biology skills; UK life-science skills sources continue to emphasize hybrid experimental and data capabilities (UK life-sciences jobs plan, Skills England life-sciences assessment, UKRI data-driven biology).

The project can develop evidence interpretation across protein interactions, chemical probes and quantitative cellular phenotypes, with possible relevance to academic research, biotechnology and drug discovery. These are potential skill pathways, not a guarantee of a drug candidate, clinical qualification or later employment. Scientific success may be a supported mechanistic distinction even if cancer selectivity is not demonstrated.

Next Actions and Questions to Verify

Before Applying

The form directs applicants to send the completed electronic application to students@lms.mrc.ac.uk, provide two academic referees and ask them to send references directly. Registering interest is not an application. The planned intake is 4 October 2027; confirm the personal start and whether the reference deadline matches the application deadline.

1. Confirm the portal deadline matches the application form wording: 18 November 2026, 9am UK time.
2. Confirm full international-fee coverage and overseas visa-cost mechanism for a Chinese awardee.
3. Confirm that Speck-Project.docx is the final project document for this round.

At Interview

1. Ask which TRF2 interaction, ORC/shelterin interface and cell model anchors year 1.
2. Ask whether purified proteins, interaction mutants, first-generation peptides or ALT-cell assays are already available.
3. Ask how supervision is divided among Speck, Barnard and Barr labs.

Before Accepting an Offer

1. Request written stipend schedule, fee coverage, CAS wording and visa-cost details.
2. Confirm expectations for peptide synthesis, delivery, normal-cell comparators, imaging throughput and data analysis support.

Evidence and Sources

The available LMS 2026–27 recruitment material and application form state the deadline and award terms, but do not establish whether applications remain open. The existing paper summaries discuss the publications by title; they do not establish complete ordered bylines, paper-level contribution statements or whether full texts and supplements were available for each item.

• Official recruitment and application: LMS 4-year PhD studentships, LMS application form PDF, project document.
• Institution and programme: LMS PhD study page, UKRI MRC institute list, Research at the LMS, QS Imperial profile.
• Supervisor/lab and papers: Speck profile, DNA Replication group, Anna Barnard profile, Barr profile, paper 1, paper 2, paper 3, TRF2-ORC field paper.
• Cost, visa and market context: Imperial living-cost estimates, UKVI financial evidence, UK life-sciences jobs plan, Skills England life-sciences assessment, UKRI data-driven biology.
• Current LMS 2026–27 application form: 9am UK time.